|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zimmermann S and Peters S: Present
standards and future perspectives in the treatment of metastatic
non-small cell lung cancer. Cancer Metastasis Rev. 34:173–182.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Azzoli CG, Giaccone G and Temin S:
American society of clinical oncology clinical practice guideline
update on chemotherapy for stage IV non-small-cell lung cancer. J
Oncol Pract. 6:39–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nascimento AV, Singh A, Bousbaa H,
Ferreira D, Sarmento B and Amiji MM: Overcoming cisplatin
resistance in non-small cell lung cancer with Mad2 silencing siRNA
delivered systemically using EGFR-targeted chitosan nanoparticles.
Acta Biomater. 47:71–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nikolaou M, Pavlopoulou A, Georgakilas AG
and Kyrodimos E: The challenge of drug resistance in cancer
treatment: A current overview. Clin Exp Metastasis. 35:309–318.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Yang SH and Guo XL: New insights
into Vinca alkaloids resistance mechanism and circumvention in lung
cancer. Biomed Pharmacother. 96:659–666. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joshi P, Vishwakarma RA and Bharate SB:
Natural alkaloids as P-gp inhibitors for multidrug resistance
reversal in cancer. Eur J Med Chem. 138:273–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pesic M, Markovic JZ, Jankovic D, Kanazir
S, Markovic ID, Rakic L and Ruzdijic S: Induced resistance in the
human non small cell lung carcinoma (NCI-H460) cell line in vitro
by anticancer drugs. J Chemother. 18:66–73. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang CH, Wang C, Ojima I and Horwitz SB:
Taxol analogues exhibit differential effects on photoaffinity
labeling of β-tubulin and the multidrug resistance associated
P-glycoprotein. J Nat Prod. 81:600–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He J, Lan X, Duan HL, Luo H and Zhou XD:
CA916798 affects growth and metastasis of androgen-dependent
prostate cancer cells. Eur Rev Med Pharmacol Sci. 22:4477–4487.
2018.PubMed/NCBI
|
|
14
|
Wang HJ, Yang HP, Zhou XD, Dai XT, Chen YF
and Xiong W: CA916798 regulates multidrug resistance of lung cancer
cells. Asian Pac J Cancer Prev. 12:3403–3408. 2011.PubMed/NCBI
|
|
15
|
Qi Z, Wang Y and Zhou X: CA916798 gene
participates in cisplatin resistance of human lung adenocarcinoma
A549 cells through PI3K/AKT/mTOR pathway. Nan Fang Yi Ke Da Xue Xue
Bao. 32:1290–1293. 2012.(In Chinese). PubMed/NCBI
|
|
16
|
Wang YL, Zhu BJ, Qi ZZ, Wang HJ and Zhou
XD: Akt1 enhances CA916798 expression through mTOR pathway. PLoS
One. 8:e623272013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang HJ, Yang ZX, Dai XT, Chen YF, Yang HP
and Zhou XD: Bisdemethoxycurcumin sensitizes cisplatin-resistant
lung cancer cells to chemotherapy by inhibition of CA916798 and
PI3K/AKT signaling. Apoptosis. 22:1157–1168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang X, Tang C, Luo H, Wang H and Zhou X:
Shp2 confers cisplatin resistance in small cell lung cancer via an
AKT-mediated increase in CA916798. Oncotarget. 8:23664–23674.
2017.PubMed/NCBI
|
|
19
|
Travis WD, Brambilla E, Rami-Porta R,
Vallières E, Tsuboi M, Rusch V and Goldstraw P; International
Staging Committee, : Visceral pleural invasion: Pathologic criteria
and use of elastic stains: Proposal for the 7th edition of the TNM
classification for lung cancer. J Thorac Oncol. 3:1384–1390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishino M, Jackman DM, Hatabu H, Yeap BY,
Cioffredi LA, Yap JT, Jänne PA, Johnson BE and Van den Abbeele AD:
New response evaluation criteria in solid tumors (RECIST)
guidelines for advanced non-small cell lung cancer: Comparison with
original RECIST and impact on assessment of tumor response to
targeted therapy. AJR Am J Roentgenol. 195:W221–W228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
da Costa DJ, Parrish JW, Singh NK and Hsia
DW: Lung cancer: Advances and insights in diagnosis, treatment, and
palliation. Am J Respir Crit Care Med. 198:667–669. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang P: Epidemiology of lung cancer
prognosis: Quantity and quality of life. Methods Mol Biol.
471:469–486. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burdett SS, Stewart LA and Rydzewska L:
Chemotherapy and surgery versus surgery alone in non-small cell
lung cancer. Cochrane Database Syst Rev. CD0061572007.PubMed/NCBI
|
|
27
|
Kim ES: Chemotherapy resistance in lung
cancer. Adv Exp Med Biol. 893:189–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ullah MF: Cancer multidrug resistance
(MDR): A major impediment to effective chemotherapy. Asian Pac J
Cancer Prev. 9:1–6. 2008.PubMed/NCBI
|
|
29
|
Zahreddine H and Borden KL: Mechanisms and
insights into drug resistance in cancer. Front Pharmacol. 4:282013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kartal-Yandim M, Adan-Gokbulut A and Baran
Y: Molecular mechanisms of drug resistance and its reversal in
cancer. Crit Rev Biotechnol. 36:716–726. 2016.PubMed/NCBI
|
|
31
|
Cnubben NH, Wortelboer HM, van Zanden JJ,
Rietjens IM and van Bladeren PJ: Metabolism of ATP-binding cassette
drug transporter inhibitors: Complicating factor for multidrug
resistance. Expert Opin Drug Metab Toxicol. 1:219–232. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sodani K, Patel A, Kathawala RJ and Chen
ZS: Multidrug resistance associated proteins in multidrug
resistance. Chin J Cancer. 31:58–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choi CH: ABC transporters as multidrug
resistance mechanisms and the development of chemosensitizers for
their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leslie EM, Deeley RG and Cole SP:
Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2,
and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol.
204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Triller N, Korosec P, Kern I, Kosnik M and
Debeljak A: Multidrug resistance in small cell lung cancer:
Expression of P-glycoprotein, multidrug resistance protein 1 and
lung resistance protein in chemo-naive patients and in relapsed
disease. Lung Cancer. 54:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roy S, Kenny E, Kennedy S, Larkin A,
Ballot J, Perez De Villarreal M, Crown J and O'Driscoll L:
MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in
non-small cell lung cancer. Anticancer Res. 27:1325–1330.
2007.PubMed/NCBI
|
|
37
|
Melguizo C, Prados J, Luque R, Ortiz R,
Caba O, Alvarez PJ, Gonzalez B and Aranega A: Modulation of MDR1
and MRP3 gene expression in lung cancer cells after paclitaxel and
carboplatin exposure. Int J Mol Sci. 13:16624–16635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chan BA and Coward JI: Chemotherapy
advances in small-cell lung cancer. J Thorac Dis. 5 (Suppl
5):S565–S578. 2013.PubMed/NCBI
|
